Zdrowie i gospodarka · 07/02/2019
FDA Announces Final Guidance for Developing Depot Buprenorphine Products for Opioid Use Disorder Treatment
The FDA has released a final guidance for industry on developing depot buprenorphine products for treating opioid use disorder, which aims to provide effective treatment options with reduced risk of misuse and abuse.
Source: Federal Register — Food and Drug AdministrationOpen original release →